Protecting rectal tissues from radiation damage in cancer treatment
Use of radioprotector in rectal cancer
This study is looking at a new treatment called BMX-001 that might help protect the healthy tissues in your rectum and anus from damage during radiation therapy for rectal cancer, aiming to reduce side effects like bowel problems while still fighting the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11026406 on NIH RePORTER |
What this research studies
This research investigates the use of a small molecule antioxidant called BMX-001 to protect normal rectal and anal tissues from damage caused by radiation therapy in patients with rectal cancer. The study aims to understand how BMX-001 can prevent complications such as bowel fibrosis and incontinence while still effectively targeting cancer cells. By focusing on the mechanisms of radiation-induced damage and the protective effects of BMX-001, the research seeks to improve patient outcomes during cancer treatment. Patients undergoing radiation therapy for rectal or anal cancers may benefit from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with rectal or anal cancer who are scheduled to receive radiation therapy.
Not a fit: Patients who are not undergoing radiation therapy for rectal or anal cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the long-term complications associated with radiation therapy for rectal cancer patients.
How similar studies have performed: Preliminary data suggest that similar antioxidant approaches have shown promise in protecting normal tissues during cancer treatments, indicating potential for success in this research.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Oberley-Deegan, Rebecca E — University of Nebraska Medical Center
- Study coordinator: Oberley-Deegan, Rebecca E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.